Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatm

Disposition of Comments

Comments received from Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment.

Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment

CYP2D6 for Tamoxifen in Breast Cancer, KRAS for anti-EGFR antibodies in Colorectal Cancer, and BCR-ABL1 for Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Disposition of Comments

Project ID: GENC0609


The Agency for Healthcare Research and Quality's (AHRQ) Technology Assessment (TA) Program supports and is committed to the transparency of its review process. Therefore, invited peer review comments and public review comments are publicly posted on the TA Program Web site at http://www.ahrq.gov/clinic/techix.htm within 3 months after the associated final report is posted.

This document presents the peer review comments and public review comments sent in response to the draft report, Update of Genetic Tests for Non-Cancer and Cancer Diseases and Conditions, which was made available for comment on the AHRQ Web site

Select for the print version (PDF file, 176 KB). Plugin Software Help.


Tables

Select for Table 1. Invited Peer Reviewer Comments

Select for Table 2. Public Reviewer Comments

Current as of October 2010


Internet Citation:

Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment: CYP2D6 for Tamoxifen in Breast Cancer, KRAS for anti-EGFR antibodies in Colorectal Cancer, and BCR-ABL1 for Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Disposition of Comments. June 2010. Rockville, MD: Agency for Healthcare Research and Quality. http://www.ahrq.gov/clinic/ta/comments/pharmgentests/


 

Current as of October 2010
Internet Citation: Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatm: Disposition of Comments. October 2010. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/research/findings/ta/pharmacogenetic-tests/index.html